We value your privacy

We use cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy. By using this site you agree to our Terms and Conditions.

ortex-logo-h
​
​
Nasdaq:REGN
logo

Regeneron Pharmaceuticals (REGN)

Nasdaq • REGN • US75886F1075

Ex-dividend 20 Nov · 0.94 USD (special)
923.34Last close
Market Closed
Ex-dividend 20 Nov · 0.94 USD (special)
Overview
Fundamentals
Events
News
Corp Actions
Index
Analysts
EPS Momentum
Holders
Dividend
Options
Shorts
Insiders
Peers
Commodity Exp
Trading Signals
Stock Scores

ORTEX Data Highlights

As of Nov 4, 2026, ORTEX estimated 2.2% of free float sold short, 2.5 days to cover, cost to borrow 0.19%. Sign up for live short interest data.

Market Cap

96.1b USD | # 223 in US

Volume

800.96k shares | 662.46m USD

Shares Outstanding

98.53m

Free Float Shares

97.80% | 96.36m

DB:RGO|
XTRA:RGO|
LSE:0R2M|
BOVESPA:REGN34|
BIT:1REGN|
WBAG:REGN

News

REGN key data

Regeneron Pharmaceuticals (Nasdaq: REGN) has a market capitalization of $96.11B. Last close $923.34 (as of 2026-11-20); 52-week range $591.52 to $991.73. ORTEX data as of 2026-11-04: short interest was 2.23% of free float, 2.5 days to cover and the average cost to borrow was 0.19%. Sign up for live short interest data.

Latest on REGN

  • Oct 15, 2026UBS Upgrades REGN to Buy as Shorts Retreat Before Earnings
  • Aug 19, 2026REGN Options Flash Caution as Analysts Race to Catch Up
  • Jun 3, 2026REGN enters earnings week down 15%, with the Street in mass target-cut mode
All REGN news on ORTEX News
  • REGN news on ORTEX News
  • ORTEX News
  • ORTEX public data
  • ORTEX Charts
  • ORTEX API

© 2026 ORTEX Technologies Ltd.